ArticleSignal transduction and targeted therapy2026
A biosafe mouse model for SARS-CoV-2 infection that more realistically simulates COVID-19 symptoms.
Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 resulting from SARS-CoV-2 infection has presented significant challenges to global health over the past several years. Animal models are essential for studying the pathogenic mechanisms of SARS-CoV-2 and facilitating the development of therapeutic strategies. Transgenic hACE2 mouse models are widely used to explore the mechanisms responsible for severe and lethal COVID-19. However, current lethal transgenic mouse models are reported to die primarily from central nervous system infection, whereas in human patients, respiratory system infection is the primary cause of death. Moreover, earlier mouse models require the use of high-containment biosafety laboratories, which significantly limits SARS-CoV-2 studies and restricts broader experimental applications. Here, we established mouse models with systemic or lung-specific expression of the SARS-CoV-2 nucleocapsid (N) protein based on the K18-hACE2 KI mice. Both strains of mice are susceptible to SARS-CoV-2 ΔN/GFP-HBiT replicon delivery particles (RDPs), allowing efficient viral replication without producing infectious virions. Notably, lung-specific N-expressing mice exhibit only pulmonary infection, with lethality and pathological features closer to the clinical presentations of COVID-19. This RDP-infected mouse model enables the evaluation of anti-SARS-CoV-2 drugs, with infection phenotypes closely resembling those of wild-type SARS-CoV-2. Overall, this model offers a safer, increasingly convenient, and more universally applicable tool for SARS-CoV-2 research and antiviral therapy development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.